The USPTO issued patent grant US12590124B2 on March 31, 2026, to CAREGEN CO, LTD. for a peptide with neutralizing activity against SARS-CoV-2. The patent covers compositions for preventing or treating coronavirus infection as well as detection compositions. Filed on July 15, 2021, as Application No. 18016046, the patent contains 13 claims assigned under CPC classifications including C07K 7/04, C07K 7/06, and A61P 31/14.

Patent holders and R&D teams in biopharmaceutical companies should review this grant to assess potential freedom-to-operate implications for COVID-19 therapeutic or diagnostic development programs. No compliance action is required—this is a patent issuance notice, not a regulatory requirement. Companies developing competing peptides or antibodies targeting SARS-CoV-2 may need to evaluate design-around options.